Selected licensing partners
Merck continues to pursue targeted, strategic collaborations with companies, institutions, academics and others as part of Merck's Plan to Win. Following are some examples of disclosed arrangements completed in 2003-2005.
| Partner/Licensor | Target/Description |
| Acumen | Alzheimer's disease |
| Actelion | Hypertension |
| AgResearch | Animal health |
| Agensys | Cancer |
| Alnylam | RNAi-ophthalmic |
| Alnylam | RNAi technology |
| AVEO | Cancer |
| Benitec | RNAi technology |
| BioXell | Sepsis |
| Celera | Alzheimer's disease |
| CSL | Vaccine adjuvant |
| deCODE | Pharmacogenomics |
| Diversa | Antibodies |
| DOV | Depression |
| FoxHollow | Atherosclerosis |
| Geron | Oncology vaccine |
| GlycoFi | Antibody platform |
| Inovio | DNA vaccine technology |
| Kinexis | Sleep disorders |
| Kyorin | Infection |
| Lundbeck | Sleep disorders |
| MerLion | Natural products |
| Metabasis | Diabetes |
| Metabasis | Hepatitis C |
| MethylGene | Antibacterials |
| MorphoSys | Antibodies |
| Nastech | Obesity |
| Neurogen | Pain |
| NicOx SA | NO compounds |
| Ono | Stroke |
| ParAllele | Cancer |
| Perlegen | Genomics |
| Pierre Fabre | Cancer |
| PPD Development | Biomarkers |
| Prosidion | Diabetes |
| Rigel | Cancer |
| Robarts | Imaging technology |
| Sumitomo | Schizophrenia |
| Sunesis | Alzheimer's disease |
| Sunesis | Antivirals |
| University of Dundee | Kinase consortium |
| Vertex | Cancer |
| XOMA | Antibodies |
| Zenyth | Respiratory |
| Znomics | Metabolic |
